BullMarket.com Offers Investment Opinion on Research In Motion, Genentech, Amgen, and DivX.PRINCETON, N.J. -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, announced today that it has provided subscribers with several detailed reports on companies making headlines including Research In Motion (Nasdaq: RIMM (Rambus Inline Memory Module) See RDRAM. See also RIM. ), Genentech (NYSE NYSE See: New York Stock Exchange : DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. ), Amgen (Nasdaq: AMGN), and DivX (Nasdaq: DIVX). BullMarket.com's Recommended List of stocks boasts six holdings that have returned over 200% since being added. All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today: https://www.bullmarket.com/subscribe/index.php?refer=BMR BMR basal metabolic rate. BMR abbr. basal metabolic rate BMR, n See basal metabolic rate. BMR basal metabolic rate. 220B In its report, BullMarket.com wrote: "In spite of the fairly positive outlook, Research In Motion stock was a bit too expensive to withstand a mediocre FQ4, and digging a bit deeper, there were one or two other red flags... Investors who bought when we first wrote up the stock in October are still looking at a nice profit, and the question now is whether this pullback is a warning for investors to get out, or perhaps a new opportunity for investors to get in..." BullMarket.com looked at the following topics, among others: -- Should investors view the post-earnings dip in RIM as a buying opportunity? At what price would the Bull Market Report recommend buying RIM? -- Is Genentech poised to surpass analyst estimates in upcoming quarters? Does the stock represent a good value at its current price? -- With Amgen way off its 52 week high, is it time to buy, or should investors stay away for now? -- Should investors be wary of the possibility that DivX may pursue a secondary offering? What will DivX's transition from its reliance on DVD players mean for the company's results going forward? About BullMarket.com: Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices. NOTE: This release was published by Indie Research Advisors, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control (CRD CRD See Central Registration Depository (CRD). #131926), a registered investment advisor Registered Investment Advisor (RIA) is a designation obtainable in the United States by an individual who has registered with the U.S. Securities and Exchange Commission or state regulatory agency (where the primary business is situated or multiple States in some cases) in with the NASD NASD See: National Association of Securities Dealers NASD See National Association of Securities Dealers (NASD). and State of NJ. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion